Therapeutic Asset Ratings
13,157 results matching 1 filter
91,583 assets · 7,906 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Selumetinib
Cutaneous Melanoma
National Cancer Institute (NCI)
P2
BB
(64)
SIMVASTATIN
Invasive Breast Carcinoma
Emory University
P2
BB
(64)
Sirolimus
Burkitt Lymphoma
Masonic Cancer Center, University of Minnesota
P2
BB
(64)
Sotorasib
Lung Cancer
National Cancer Institute (NCI)
P2
BB
(64)
Sugemalimab
Refractory Malignant Neoplasm
Second Affiliated Hospital of Soochow University
P2
BB
(64)
TACROLIMUS
Essential Thrombocythemia
Thomas Jefferson University
P2
BB
(64)
TACROLIMUS
Adult T-Cell Leukemia/Lymphoma
Thomas Jefferson University
P2
BB
(64)
TACROLIMUS
Myelodysplastic Syndrome With Single Lineage Dysplasia
Masonic Cancer Center, University of Minnesota
P2
BB
(64)
Talazoparib
Her2-Receptor Negative Breast Cancer
National Cancer Institute (NCI)
P2
BB
(64)
TESTOSTERONE CIPIONATE
Castration-Resistant Prostate Carcinoma
Roswell Park Cancer Institute
P2
BB
(64)
Thiotepa
Chronic Granulomatous Disease
University of Florida
P2
BB
(64)
Thiotepa
Common Variable Immunodeficiency
University of Florida
P2
BB
(64)
Thiotepa
Congenital Amegakaryocytic Thrombocytopenia
Fred Hutchinson Cancer Center
P2
BB
(64)
Thiotepa
Hematologic Disorder
Baptist Health South Florida
P2
BB
(64)
Thiotepa
Hemophagocytic Syndrome
University of Florida
P2
BB
(64)
Thiotepa
Hurler Syndrome
University of Florida
P2
BB
(64)
Thiotepa
Severe Combined Immunodeficiency
St. Jude Children's Research Hospital
P2
BB
(64)
Thiotepa
Wiskott-Aldrich Syndrome
University of Florida
P2
BB
(64)
Thiotepa
X-Linked Lymphoproliferative Syndrome
University of Florida
P2
BB
(64)
TIPIRACIL
Colon Adenocarcinoma
Academic and Community Cancer Research United
P2
BB
(64)
TIPIRACIL
Colorectal Adenocarcinoma
Academic and Community Cancer Research United
P2
BB
(64)
TIPIRACIL
Rectum Adenocarcinoma
Sir Run Run Shaw Hospital
P2
BB
(64)
TIPIRACIL
Colon Carcinoma
Academic and Community Cancer Research United
P2
BB
(64)
Tislelizumab
Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University
P2
BB
(64)
TRASTUZUMAB
Rectal Cancer
Academic and Community Cancer Research United
P2
BB
(64)
Showing 876 to 900 of 13,157 assets
Previous
Page 36 of 527
Next